Low-dose Clozapine in the Treatment of Levodopa-Induced Mental Disturbances in Parkinson's Disease
Tóm tắt
Từ khóa
Tài liệu tham khảo
Rondot R, de Recondo J, Coignet A, Ziegler M. Mental disorders in Parkinson's disease after treatment with L-Dopa. Adv Neurol 1984;40:259-269.
Sacks OW, Kohl MS, Messeloff CR, Schwartz WF. Effects of levodopa in parkinsonian patients with dementia. Neurology 1972;22:516-519.
Cummings JL. Behavioral complications of drug treatments of Parkinson's disease. J Am Geriatr Soc 1991;39:708-716.
Baldessarini RJ, Frankenburg FR. Drug therapy: clozapine--a novel antipsychotic agent. N Engl J Med 1991;324:746-754.
Van Tol HH, Bunzow JR, Guan HC, et al. Cloning of the gene for a human dopamine D sub 4 receptor with high affinity for the antipsychotic clozapine. Nature 1991;350:610-614.
Wolters EC Hurwitz TA Peppard RF Calne DB. Clozapine: an antipsychotic agent in Parkinson's disease? Clin Neuropharmacol 1989:12:83-90.
Pfeiffer RF, Kang J, Graber B, Hofman R, Wilson J. Clozapine for psychosis in Parkinson's disease. Mov Disorders 1990;5:239-242.
Factor SA, Brown D. Clozapine prevents recurrence of psychosis in Parkinson's disease. Mov Disorders 1992;7:125-130.
Green P, Cote L, Fahn S. Treatment of drug-induced Parkinson's disease with clozapine. In: Narabayashi H, Nagatsu T, Yanagisawa N, Mizuno Y, eds. Advances in Neurology. New York: Raven Press, 1993;60:703-706.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed revised. Washington DC 1987.
Simpson GM, Cooper TA. Clozapine plasma levels and convulsions. Am J Psychiatry 1978;135:99-100.
Devinsky O, Honigfeld G, Patin J. Clozapine-related seizures. Neurology 1991;41:369-371.
Webster DD. Critical analysis of the disability in Parkinson's disease. Mod Treatm 1968;5:257-282.
Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 1993;43:2227-2229.
Pakkenberg H, Pakkenberg B. Clozapine in the treatment of tremor. Acta Neurol Scand 1986;73:295-297.
Friedman JH, Lannon MC. Clozapine-responsive tremor in Parkinson's disease. Mov Disorders 1990;5:225-229.
Fischer PA, Baas H, Hefner R. Treatment of parkinsonian tremor with clozapine. J Neural Transm 1990;2:233-238.
Jansen ENH. Clozapine in the treatment of tremor in Parkinson's disease. Acta Neurol Scand 1994;89:262-265.
Sokoloff P, Giros B, Martres MP, Boutehenet MI, Schwartz JC. Molecular cloning and characterization of a novel dopamine receptor (D sub 3) as a target for neuroleptics. Nature 1990;347:146-150.
Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ, Shen Y. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 1994;268:1403-1410.
Fernstrom JD, Wurtman RJ. Brain serotonin content: physiological regulation by plasma neutral amino acids. Science 1972;173:149-152.
Canton H, Verriele L, Colpaert FC. Binding of typical and atypical antipsychotics to 5-HT1C and 5-HT sub 2 sites: cloza- pine potently interacts with 5-HT1C sites. Eur J Pharmacol 1990;191:93-96.
Meltzer HY. The importance of serotonin-dopamine interactions in the action of clozapine. Br J Psychiatry 1992;160(suppl 2):22-29.
Zoldan J Friedberg G Goldberg-Stern H Melamed E. Ondansetron for hallucinosis in advanced Parkinson's disease (letter). Lancet 1993;341(8844):562-563.
Lieberman JA, Johns CA, Kane JM, et al. Clozapine- induced agranulocytosis: non-cross reactivity with other psychotropic drugs. J Clin Psychiatry 1988;49:271-277.
Ryabik BM, Nguyen VT, Mann RM, Smith JD, Lippman SB. Clozapine-induced agranulocytosis and colony-stimulating cytokines. Gen Hosp Psychiatry 1993;15:263-265.